Leriva’s company structure is comprised of four legal entities all of which are incorporated and registered in Greece as Sociétés Anonymes. To instill a common identity across all customer segments and effectively promote the group as whole, all the legal entities operate under the Leriva banner. Leriva Holdings SA serves as the holding company and ultimate parent of the group’s operating companies, namely Leriva SA, Leriva Diagnostics SA and Leriva Pharma SA (formerly Leriva Imaging SA).
In terms of distribution and licensing agreements, in addition to Beckman Coulter and Sciex, both of which are members of the Danaher family of companies, Leriva Diagnostics SA is also the counterparty to distribution agreements with a host of other companies that are engaged in In Vitro Diagnostics (IVD), Life Sciences and Molecular Diagnostics (MDx).
Leriva Pharma SA (formerly Leriva Imaging SA) has two distinct businesses. Firstly, Imaging and Contrast Media where it is the counterparty to the distribution agreements with the Bracco companies. And secondly, Consumer Health Care where a wide and growing range of products are marketed under the proprietary Immuvit brand name.
Commercially, Leriva SA is active in the Transfusion Technology segment and is the counterparty to the distribution agreement with Fresenius Kabi. In addition to its commercial activities, Leriva SA also provides support services such as Finance & Administration, Human Resources, Information Technology and Logistics to all the other Leriva companies under the group’s shared services arrangement.
In terms of distribution and licensing agreements, in addition to Beckman Coulter and Sciex, both of which are members of the Danaher family of companies, Leriva Diagnostics SA is also the counterparty to distribution agreements with a host of other companies that are engaged in In Vitro Diagnostics (IVD), Life Sciences and Molecular Diagnostics (MDx).
Leriva Pharma SA (formerly Leriva Imaging SA) has two distinct businesses. Firstly, Imaging and Contrast Media where it is the counterparty to the distribution agreements with the Bracco companies. And secondly, Consumer Health Care where a wide and growing range of products are marketed under the proprietary Immuvit brand name.
Commercially, Leriva SA is active in the Transfusion Technology segment and is the counterparty to the distribution agreement with Fresenius Kabi. In addition to its commercial activities, Leriva SA also provides support services such as Finance & Administration, Human Resources, Information Technology and Logistics to all the other Leriva companies under the group’s shared services arrangement.
